Published by Global Banking and Finance Review
Posted on January 5, 2026
LONDON, Jan 5 (Reuters) - Britain's medicines regulator said on Monday it was reviewing Novo Nordisk's application for an oral 25 milligram version of its weight-loss drug Wegovy and anticipated making a decision before the end of the year.
Novo is launching its once-daily Wegovy pill in the United States on Monday, hoping to regain ground lost to U.S. rival Eli Lilly and attract new, needle-wary consumers.
The Danish drugmaker has previously said it submitted applications for the pill to the European Medicines Agency and other regulatory bodies in the second half of 2025.
(Reporting by Bhanvi Satija; Editing by Emelia Sithole-Matarise)
Wegovy is an FDA-approved weight-loss medication developed by Novo Nordisk, designed to help individuals manage obesity through appetite regulation.
The European Medicines Agency (EMA) is a regulatory body that evaluates and supervises medicinal products in the European Union to ensure their safety and efficacy.
A weight-loss drug is a medication prescribed to help individuals lose weight by suppressing appetite, increasing feelings of fullness, or reducing the absorption of fat.
Regulatory approval for drugs is crucial as it ensures that the medication has been thoroughly tested for safety and efficacy before being made available to the public.
Explore more articles in the Finance category
